By Piranha Profits Team
Last updated on September 11, 2026
Philip Morris International posted its first $11.2 billion revenue quarter, with organic growth accelerating to 7.6% and smoke-free products crossing 42% of net revenue, and the same quarter carried a $511 million non-cash impairment on its Canadian affiliate that shaved $0.33 off adjusted earnings.
Zyn pouch shipments keep climbing and IQOS is now running as an independent U.S. business after Philip Morris took the brand back from Altria in 2024, and the market has to decide whether that growth curve is compounding fast enough to keep servicing a balance sheet still carrying Swedish Match acquisition debt.
PM Business Segment Powered by StockOracle™ Accurate as of 11th September 2026.
Is Philip Morris International's intrinsic value already ahead of the smoke-free story, or is Wall Street pricing in a transition that still has to prove it can carry the whole company?
What is Philip Morris International's intrinsic value?
Intrinsic value is what a business is actually worth based on the cash it can realistically generate, not what the market happens to pay for the stock. For a tobacco company mid-transition like Philip Morris, that comes down to if the smoke-free growth engine can keep outrunning cigarette volume decline for long enough to justify the cash flow.
PM Intrinsic Value: The DCF Fair Value Result
Philip Morris trades at $185.71 (10th Sep 2026), or 26.55 times trailing earnings and 20.21 times forward earnings.
Run through StockOracle's own 20-year discounted cash flow model (DCF-20), built on Philip Morris's estimated 6.72% weighted average cost of capital, fair value comes out near $208.93 per share.
On the multiples side, StockOracle's mean price-to-earnings model, stripping out non-recurring items, values the stock near $150.41 at a 21.61x multiple, the median version lands at $130.72 at 18.78x, and the mean price-to-sales model puts it at $144.68 at 5.32x sales.
That spread, a cash-flow-based DCF near $209 against earnings- and sales-based multiples clustered closer to $130 to $150, is the more honest story than any single figure: the market is still pricing part of Philip Morris on the multiple it thinks the smoke-free mix deserves, not purely on discounted cash.
Price-to-book is similarly not meaningful here: decades of share buybacks have pushed book value negative, so P/B ratio reads as -33.72, a number that says more about the buyback history than about value.
Growth-adjusted, the stock's price-to-sales-to-growth ratio sits at 1.15 and its price-to-earnings-to-growth ratio, stripping non-recurring items, at 2.71. Neither number screams cheap on a pure growth-adjusted basis, which lines up with a DCF-20 estimate that sits above the market price while several of the earnings- and sales-based models sit below it.
Wall Street's own published targets span from $180 to $225 among the 12 analysts MarketBeat tracks, a spread that shows real disagreement about how much credit the smoke-free transition deserves. The DCF-20 figure above sits comfortably inside that range.
Philip Morris carries meaningfully more leverage than a typical consumer staple: debt to EBITDA of 2.74x and interest coverage of 10.51x. A portion of the free cash flow any DCF model projects has to first cover interest and gradual deleveraging before it's genuinely discretionary for dividends or reinvestment, which is plausibly one reason management has said there will be no share repurchases in 2026. That doesn't invalidate the DCF-20 estimate, it just means the cash flow being discounted is claimed by more than equity holders alone right now.
Philip Morris International (PM) Financial Performance
Revenue Growth: A Pricing and Mix Story
PM Revenue Trend — Powered by StockOracle™ · Accurate as of 10 September 2026
Philip Morris's second-quarter 2026 net revenue reached $11.2 billion, up 10.4% reported and 7.6% organically, on top of first-half 2026 revenue of $21.3 billion. On a trailing basis, its revenue $42.45 billion, up from $40.54 billion for full-year 2025, a five-year growth rate of 7.15% that has moderated to 4.29% on a ten-year view.
International combustible net revenue grew 6.4% organically in the quarter even as cigarette shipment volumes kept falling, which means pricing and product mix are carrying more of that growth than units sold.
Free Cash Flow: What Actually Funds the Dividend
Free cash flow is the cash that actually moves through the business after the bills are paid. On a trailing basis, StockOracle™ shows Philip Morris converting $14.26 billion of operating cash flow into $12.72 billion of free cash flow after $1.54 billion of capital spending, or $8.16 of free cash flow per share.
That's a free cash flow yield of 4.42% on the current share price.
Operating Cash Flow and Free Cash Flow Chart — Powered by StockOracle™ · Accurate as of 10 September 2026
Rule of 40 score for Philip Morris, revenue growth plus free cash flow margin, sits at 48.91%, comfortably above the 40% threshold investors typically use to flag a healthy balance between growth and profitability for a maturing business.
Smoke-Free Mix and Pricing: The Segment Doing the Compounding
Smoke-free products made up 42% of Philip Morris's total net revenue in the second quarter of 2026, up from 41.5% for the full 2025 year, and that segment's net revenue grew 11.8% organically in the quarter versus 6.4% for international combustibles. At a continued organic growth pace in the low teens, the smoke-free business would roughly double in size in under six years (doubling time of about 5.7 years at 13% annual growth), which is a real compounding trajectory.
IQOS is now sold directly by Philip Morris in the U.S. rather than through Altria, and smoke-free products are available in 109 markets, both concrete distribution levers behind that growth rate.
Shareholder Returns: The Dividend Is Doing ALL the Work Right Now
Philip Morris raised its quarterly dividend 8.9% to $1.47 per share in September 2025, which works out to $5.88 in trailing dividends per share and a yield near 3.18%. The payout ratio, however, sits at 84.52% of trailing earnings, leaving a thinner cushion before buybacks or extra debt paydown could compete for that cash.
Do your own Dividend Calculations with StockOracle™ Dividend Total Returns Calculator
Management has said there will be no share repurchases in 2026, so shareholder return is running entirely through the dividend rather than a shrinking share count for now, and the historical run of annual increases is not a guarantee that any future increase will be as large or as certain.
Growth Catalysts
- Smoke-free net revenue reached 42% of total net revenue in Q2 2026, up from 41.5% for full-year 2025, and grew 11.8% organically in the quarter.
- ZYN nicotine pouch shipments reached 2.9 billion units in the quarter.
- IQOS now operates as a Philip Morris-run business in the U.S. following the end of its licensing arrangement with Altria on April 30, 2024, removing a partner from the largest single heated-tobacco opportunity market.
- Smoke-free products are now sold in 109 markets, expanding the addressable base for both IQOS and ZYN.
- Full-year 2026 operating cash flow guidance sits near $13.5 billion, up from the roughly $14.3 billion of operating cash flow already generated on a trailing basis today.
Why it matters for valuation: StockOracle™ projects Philip Morris's 3-to-5-year EPS growth at 9.84%, long-term EPS growth near 10.13%, and 3-to-5-year cash-flow-per-share growth higher still at 11.15%, and the DCF-20 model above assumes the growth mix keeps shifting toward smoke-free at something close to its current pace to hit those numbers.
If segment organic growth decelerates meaningfully, those growth assumptions feeding the model would need to come down.
Economic Moat: What Protects Philip Morris's Pricing Power
StockOracle™ rates Philip Morris a Wide Moat business, and that rating rests on a handful of specific, hard-to-replicate advantages.
Its distribution network spans more than 175 countries outside the United States, built over more than a century of navigating markets Altria has never had to operate in.
IQOS has cleared modified-risk and premarket authorization reviews in multiple jurisdictions, a regulatory gate that a new entrant would have to clear market by market rather than all at once. Retail-shelf relationships across international convenience and tobacco channels, and the installed base of IQOS device owners already inside its heated-tobacco ecosystem, round out the list.
Rivals still carry their own specific advantages, not copies of Philip Morris's.
British American Tobacco matches Philip Morris's global combustible manufacturing scale and runs a parallel reduced-risk ecosystem of its own, the Vuse vapor line and the glo heated-tobacco device.
Japan Tobacco holds an entrenched incumbent position in specific geographies, including Russia, Eastern Europe, and Japan itself.
The IQOS device and its HEETS consumable sticks work something like an espresso machine: the device is a modest one-time purchase, but every stick after that has to be Philip Morris's own consumable, and an adult smoker who has already switched faces a real cost, a new device, a new habit, a new supply relationship, to move to a competitor's system instead.
That protects pricing power on both sides of the business, cigarettes and smoke-free alike, which is the mechanism behind combustible net revenue still growing organically even as volumes decline.
Regulation is the one force that can dent this moat directly rather than just compete against it. The FDA has authorized 20 ZYN products across 10 flavors for legal U.S. sale, but roughly 15 U.S. states were weighing flavor bans on nicotine pouches by late 2025, with some municipalities already enacting restrictions in early 2026. Which is a real and ongoing risk to the smoke-free growth rate the DCF-20 model depends on, separate from the litigation and excise-tax risk that has always shadowed the combustible side of the business.
Building Your Own Philip Morris (PM) Intrinsic Value Estimate
Nudge the discount rate up from the 6.72% WACC baseline toward 8% to 9% to build in more litigation and regulatory tail risk, and slow the growth assumptions behind the model toward the high single digits, rather than assuming the current low-teens smoke-free pace holds indefinitely.
Readers can run their own growth assumptions through a free StockOracle™ trial rather than taking the base case above at face value.
Final Thoughts on Philip Morris International's Intrinsic Value
- Smoke-free products already generate 42% of net revenue and grew 11.8% organically in the latest quarter, a pace that would roughly double the segment in under six years if sustained.
- Net pricing power is still offsetting cigarette volume decline, shown by international combustible net revenue growing 6.4% organically even as units sold keep falling.
- Operating margin of 37.32% and trailing free cash flow of $12.72 billion, give the business real capacity to keep funding its dividend and paying down acquisition debt at the same time.
- The dividend yields roughly 3.18% today and was raised 8.9% in September 2025, though a payout ratio of 84.52% of trailing earnings and the pause on 2026 buybacks show management prioritizing debt reduction and dividend coverage over faster shareholder returns for now.
- IQOS now runs as an independent U.S. business and smoke-free products reach 109 markets, both concrete expansion levers rather than hypothetical ones.
- Leverage sits at 2.74x debt to EBITDA with interest coverage of 10.51x, per StockOracle™, even without help from a buyback program this year.
None of this erases the pessimism embedded in Philip Morris's stock right now and a regulatory and litigation backdrop that never fully goes away for a tobacco company.
The DCF-20 model puts intrinsic value near $208.93 per share, built on the belief that the smoke-free pricing and volume engine keeps compounding roughly the way it has for the last several quarters. If that engine keeps running, this estimate has room to compound higher over time; if cigarette volumes fall faster than smoke-free growth can replace them, or flavor restrictions slow ZYN's expansion meaningfully, it's this same estimate, and the earnings-based models already sitting well below it, that have the furthest to fall.
